To investigate the efficacy, safety, and compliance of a simplified strategy using vonoprazan plus clarithromycin for first-line treatment in patients with Helicobacter pylori infection, among those infected with strains without clarithromycin resistance gene mutations based on fecal clarithromycin resistance gene detection.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
70
Participants receive vonoprazan 20 mg orally twice daily plus clarithromycin 500 mg orally twice daily for 14 consecutive days.
Peking University First Hospital
Beijing, Beijing Municipality, China
RECRUITINGEradication rate of H. pylori
H. pylori eradication rate assessed by¹³C-urea breath test at 4 weeks after the completion of treatment.
Time frame: 4 weeks after the completion of treatment
incidence of adverse reactions
The incidence of adverse reactions refers to the proportion of participants who experience any adverse reactions related to the study drugs (vonoprazan and clarithromycin) during the 14-day medication period.
Time frame: At the end of the 14-day medication period (Day 14)
Compliance
Medication compliance rate (proportion of participants with good compliance, defined as compliance rate ≥ 80%).
Time frame: At the end of the 14-day medication period (Day 14)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.